BridgeBio Pharma, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BBIO in the last 30 days.
See all $BBIO insider activity →BridgeBio Pharma (Nasdaq: BBIO) will release its Q3 2026 financial results and business update on Oct. 29, 2026, after market close. The company will host a conference call at 4:30 pm ET to discuss the results and program updates. A webcast will be available on the company's website, with a replay accessible for 30 days.
Oppenheimer reduced its price target for BridgeBio Oncology Therapeutics to $16 from $22, while maintaining an Outperform rating. The stock has seen a 5-day change of +2.28%, a 1st Jan change of -12.58%, and a year-to-date change of -77.24%. The company's ratings are based on various composite factors including valuation, EPS revisions, and visibility.
Piper Sandler maintained an Overweight rating on BridgeBio Pharma (BBIO) and raised its price target to $120 from $115, citing growth potential in the biotech sector. The company's GF Value™ suggests it is 59.4% undervalued, but its GF Score™ indicates moderate performance with strong growth but weak financial strength. Insider selling activity totaled $4.58M over the last three months.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BBIO (BridgeBio Pharma, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BBIO coverage spans financial news, earnings and regulation.
The announcement may prompt short-term positioning ahead of the earnings release.
Analyst price target cut suggests lower near-term upside.
Analyst upgrade may lift the stock as investors price in the higher target.
Analyst price‑target cut suggests weaker outlook.
Positive trial results could boost BBIO's valuation and support price target upgrades.
AlphAI scores every news story that mentions BBIO with an AI model for sentiment and relevance, and aggregates insider trades from BridgeBio Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BridgeBio Pharma (Nasdaq: BBIO) will release its Q3 2026 financial results and business update on Oct. 29, 2026, after market close. The company will host a conference call at 4:30 pm ET to discuss the results and program updates. A webcast will be available on the company's website, with a replay accessible for 30 days.
1 min readOppenheimer reduced its price target for BridgeBio Oncology Therapeutics to $16 from $22, while maintaining an Outperform rating. The stock has seen a 5-day change of +2.28%, a 1st Jan change of -12.58%, and a year-to-date change of -77.24%. The company's ratings are based on various composite factors including valuation, EPS revisions, and visibility.
1 min readPiper Sandler maintained an Overweight rating on BridgeBio Pharma (BBIO) and raised its price target to $120 from $115, citing growth potential in the biotech sector. The company's GF Value™ suggests it is 59.4% undervalued, but its GF Score™ indicates moderate performance with strong growth but weak financial strength. Insider selling activity totaled $4.58M over the last three months.
2 min readBofA Securities reduced its price target for BridgeBio Pharma (BBIO) from $104 to $102 while maintaining a 'Buy' rating. The company focuses on genetic disease treatments, with multiple programs in development, including Attruby and Beyonttra for TTR Amyloidosis.
1 min readH.C. Wainwright reiterated a Buy rating and $120 price target for BridgeBio Pharma (BBIO) after positive Phase 3 trial data for encaleret. The stock trades near its fair value estimate, with a Strong Buy consensus and targets ranging from $80 to $156. BridgeBio also announced FDA acceptance of a New Drug Application for infigratinib, with a target action date in February 2027.
2 min readUBS initiated coverage of BridgeBio Pharma (BBIO) with a Buy rating and a $92 price target, citing underestimation of its lead drug's potential. UBS projects 2035 sales of $4.1B, higher than the $3.7B consensus. The firm's optimism is based on a 50-doctor survey, comparative data, and recent real-world evidence.
2 min readBridgeBio's NDA for oral infigratinib in achondroplasia received FDA Priority Review, with a PDUFA date of Feb 4, 2027. The treatment met primary and secondary endpoints in the PROPEL 3 trial, showing significant height and proportionality improvements. BridgeBio anticipates a U.S. launch if approved, according to the company.
1 min readBridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significa
2 min readTruist Securities previewed Q3 2026 earnings for eight biotech companies, highlighting Insmed (INSM), BridgeBio (BBIO), and Neurocrine (NBIX) for potential volatility. Insmed's Brinsupri forecast was reduced due to lower prescription trends. BridgeBio's revenue surged 202% to $713M with 94% gross margins. The FDA accepted BridgeBio's NDA for infigratinib, with analysts maintaining Buy ratings and price targets.
7 min readBridgeBio Pharma (BBIO) closed at $65.35 on Oct. 9, down 28% from its July high. Barclays reaffirmed its Overweight rating and $156 target, implying 139% upside. The company reported wider-than-expected Q2 losses and shrinking patient switch pool for Attruby, despite $222.4M in U.S. sales. The FDA's Nov. 27 decision on BBP-418 is a key upcoming event.
2 min read
